INT12632

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.38
First Reported 1991
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 13
Total Number 15
Disease Relevance 6.54
Pain Relevance 6.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
caudate nucleus 9
putamen 5
parietal cortex 2
globus pallidus 2
INSRR (Homo sapiens)
Pain Link Frequency Relevance Heat
gABA 59 100.00 Very High Very High Very High
Cannabinoid 32 100.00 Very High Very High Very High
Dopamine 24 100.00 Very High Very High Very High
adenocard 24 100.00 Very High Very High Very High
opioid receptor 10 100.00 Very High Very High Very High
Opioid 4 97.08 Very High Very High Very High
Pain 9 95.20 Very High Very High Very High
Potency 4 94.64 High High
agonist 2 94.24 High High
Kappa opioid receptor 2 93.92 High High
Disease Link Frequency Relevance Heat
Cancer 318 99.28 Very High Very High Very High
Disease 108 99.18 Very High Very High Very High
Pain 8 95.20 Very High Very High Very High
Targeted Disruption 6 93.12 High High
Breast Cancer 126 86.60 High High
Pathologic Neovascularization 3 72.48 Quite High
Advanced Or Metastatic Breast Cancer 18 62.48 Quite High
Metastasis 12 48.52 Quite Low
Infarction 3 44.00 Quite Low
Hypoxia 54 29.40 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Second, intermediate neuropathological grades (grades 1, 2) showed a further marked decrease of CB(1) receptor binding in the caudate nucleus and putamen; this was associated with a loss of D(1) receptors in the caudate nucleus and putamen and a loss of both CB(1) and D(1) receptors in the substantia nigra.
Negative_regulation (decrease) of ) receptor Binding (binding) of in putamen associated with substantia nigra
1) Confidence 0.38 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.55 Pain Relevance 0.61
However, a focal reduction of opioid receptor binding was observed and quantitated in the primary motor/sensory strip when compared to surrounding parietal cortex.
Negative_regulation (reduction) of receptor Binding (binding) of in parietal cortex associated with opioid receptor
2) Confidence 0.33 Published 1991 Journal Neurosci. Lett. Section Abstract Doc Link 1650933 Disease Relevance 0.26 Pain Relevance 0.81
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
3) Confidence 0.28 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.59 Pain Relevance 0.58
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
4) Confidence 0.27 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
Second, intermediate neuropathological grades (grades 1, 2) showed a further marked decrease of CB(1) receptor binding in the caudate nucleus and putamen; this was associated with a loss of D(1) receptors in the caudate nucleus and putamen and a loss of both CB(1) and D(1) receptors in the substantia nigra.
Negative_regulation (decrease) of ) receptor in caudate nucleus Binding (binding) of in putamen associated with substantia nigra
5) Confidence 0.13 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.55 Pain Relevance 0.61
The inhibition of 3H-muscimol binding to the GABA(A) receptor is likely to be exclusively due to GABA present in the extract.
Negative_regulation (inhibition) of ) receptor Binding (binding) of associated with gaba
6) Confidence 0.12 Published 2001 Journal Pharmacopsychiatry Section Abstract Doc Link 11518063 Disease Relevance 0 Pain Relevance 0.46
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in putamen Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
7) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.59 Pain Relevance 0.58
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in globus pallidus Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
8) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.59 Pain Relevance 0.58
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in globus pallidus Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
9) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
First, the very early stages of the disease (grade 0) were characterized by a major loss of cannabinoid CB(1), dopamine D(2) and adenosine A(2a) receptor binding in the caudate nucleus, putamen and globus pallidus externus and an increase in GABA(A) receptor binding in the globus pallidus externus.
Negative_regulation (loss) of ) receptor in putamen Binding (binding) of in caudate nucleus associated with gaba, adenocard, dopamine, cannabinoid and disease
10) Confidence 0.09 Published 2000 Journal Neuroscience Section Abstract Doc Link 10828533 Disease Relevance 0.58 Pain Relevance 0.55
Bevacizumab recognizes all isoforms of VEGF-A and thereby prevents receptor binding, which leads to inhibition of angiogenesis and tumour growth.
Negative_regulation (prevents) of receptor Binding (binding) of associated with cancer
11) Confidence 0.01 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.71 Pain Relevance 0
Bevacizumab is a recombinant VEGF antibody derived from a humanized murine monoclonal antibody that can recognize all known isoforms of VEGF-A and prevents receptor binding, thereby inhibiting angiogenesis and tumour growth.
Negative_regulation (inhibiting) of receptor Binding (binding) of associated with cancer
12) Confidence 0.01 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.50 Pain Relevance 0
Bevacizumab is a recombinant VEGF antibody derived from a humanized murine monoclonal antibody that can recognize all known isoforms of VEGF-A and prevents receptor binding, thereby inhibiting angiogenesis and tumour growth.
Negative_regulation (prevents) of receptor Binding (binding) of associated with cancer
13) Confidence 0.01 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2246178 Disease Relevance 0.49 Pain Relevance 0
Our first published studies indicated that Salvinorin A weakly inhibited mu-receptor binding, and subsequent experiments revealed that Salvinorin A partially inhibited mu-receptor binding.
Negative_regulation (inhibited) of receptor Binding (binding) of
14) Confidence 0.01 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17060492 Disease Relevance 0 Pain Relevance 0.27
Our first published studies indicated that Salvinorin A weakly inhibited mu-receptor binding, and subsequent experiments revealed that Salvinorin A partially inhibited mu-receptor binding.
Negative_regulation (inhibited) of receptor Binding (binding) of
15) Confidence 0.01 Published 2007 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 17060492 Disease Relevance 0 Pain Relevance 0.26

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox